1761P - Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance
| Autor: | Thein, K.Z., Sultan, A., Zaw, M.H., Han, M.M., Yu, N.H., Igid, H.P., Jones, C., D'Cunha, N., Awasthi, S., Hardwicke, F. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|